WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops
targeted antibody-based anticancer products, today announced that the
following presentations by Company management at upcoming investor
conferences will be webcast:
Bank of America Merrill Lynch 2012 Health Care Conference
8:40
am PT (11:40 am ET) on May 16, 2012 in Las Vegas, NV
Presenter:
Gregory Perry, Executive Vice President and CFO
Jefferies 2012 Global Healthcare Conference
9:30 am ET on
June 6, 2012 in New York, NY
Presenter: Daniel Junius, President
and CEO
The webcast of each presentation can be accessed live through the "Investor
Information" section of the Company's website, www.immunogen.com;
a replay of each presentation will be available at the same location for
one week.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using the
Company's expertise in tumor biology, monoclonal antibodies, potent
cancer-cell killing agents and engineered linkers. The Company's
Targeted Antibody Payload (TAP) technology uses monoclonal antibodies to
deliver one of ImmunoGen's proprietary cancer-cell killing agents
specifically to tumor cells. There are now numerous TAP compounds in
clinical development with a wealth of clinical data reported.
ImmunoGen's collaborative partners include Amgen, Bayer HealthCare,
Biotest, Lilly, Novartis, Roche, and Sanofi. The most advanced compound
using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in
Phase III testing through the Company's collaboration with Genentech, a
member of the Roche Group. More information about ImmunoGen can be found
at www.immunogen.com.
Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive
Director, Investor Relations and
Corporate Communications
info@immunogen.com
Source: ImmunoGen, Inc.
News Provided by Acquire Media